Research Solutions heads into its next report carrying a narrative that has quietly cracked over the last two quarters, and this release will show whether the crack is widening or stabilizing. Consensus calls for revenue of $11.9 million, down 4.3% year over year, and EPS of $0.03, down sharply from $0.07 a year ago and flat sequentially versus last quarter's $0.03. That is not a company in freefall, but it is a company whose growth engine has clearly cooled, and the Street's forecast of a revenue decline confirms that this is expected to be a down quarter rather than a pause before reacceleration.
The most important thread coming out of the prior call is the steady deceleration in annual recurring revenue growth, which fell from 23% to 21% to 14% over three consecutive quarters, alongside incremental ARR additions that shrank from a record $1.2 million to just $560,000 last quarter. Management was explicit that transaction revenue, which already dropped to $6.6 million from $7.3 million a year ago, would keep declining through the back half of the fiscal year due to one churned account and softer volume among several large customers. This upcoming report sits squarely in that guided window, so the real question is not whether transactions fall, but whether the decline matches what management flagged or turns out to be worse. A transaction number that undershoots the soft guidance, or a further slide in active customers from the 1,321 reported last quarter, would validate the bears' concern that B2C headwinds and large-account churn are becoming structural rather than one-off.
On the other side of the ledger, the profitability and mix story has been the one clean bright spot, and this quarter needs to keep delivering on it. Gross margin has expanded for three straight quarters, from 49.5% to 52.4%, driven by platform revenue climbing to 44% of the mix with margins near 88%. Adjusted EBITDA grew 36% year over year to $1.3 million and operating cash flow rose 35% to $1.4 million, evidence that the company is monetizing its shift toward high-margin API and platform revenue even as top-line growth slows. If margin expansion stalls or reverses this quarter, it would suggest the mix shift is losing steam just as transaction revenue erodes, a combination that would meaningfully weaken the bull case. Continued margin gains, even against a shrinking top line, would show the pivot toward platform and API revenue is durable enough to offset softer legacy demand.
The newer catalysts introduced last quarter, particularly the larger API and MCP infrastructure deals running two to five times the size of traditional seat-based contracts, and the B2C2B pipeline that grew from roughly $50,000 to over $1 million, remain too early-stage to expect major revenue contribution yet. But any commentary on deal conversion, additional large API wins beyond the single pharma account cited previously, or traction for the RightsDell AI-rights product would matter more than the raw numbers this quarter, since these are the threads management pointed to as the eventual replacement for softening transaction and B2C revenue.
Sentiment heading into the print has turned more bearish, with EarningsWhispers showing 76.7% bearish positioning versus 67.2% last quarter, and the stock has underperformed the S&P 500 by nearly nine percentage points since the last report while trading below its 200-day moving average. That combination suggests expectations have already been marked down, which lowers the bar for a modest beat but raises the stakes if transaction declines or customer attrition come in worse than the softer guidance implied. The central issue for this report is whether the margin and platform-mix story can keep offsetting a shrinking transaction and B2C base, or whether deceleration spreads further and forces a harder reset of growth expectations.